Comparative Pharmacology
Head-to-head clinical analysis: NAFCILLIN SODIUM versus VEETIDS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAFCILLIN SODIUM versus VEETIDS.
NAFCILLIN SODIUM vs VEETIDS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nafcillin exerts bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
VEETIDS (generic: voretigene neparvovec) is an adeno-associated virus vector-based gene therapy that delivers a functional copy of the RPE65 gene to retinal pigment epithelial cells, restoring the visual cycle and improving vision in patients with biallelic RPE65 mutation-associated retinal dystrophy.
1-2 g IV every 4 hours; or 1-2 g IM every 4-6 hours.
500 mg orally twice daily for 7-14 days.
None Documented
None Documented
Approximately 0.5 hour (30 minutes) in adults with normal renal function; prolonged to 1-2 hours in neonates or severe renal impairment. Clinically relevant for dosing every 4-6 hours.
Terminal elimination half-life is 1.5-2 hours in adults with normal renal function; extends to 6-10 hours in moderate renal impairment.
Primarily renal (30-40% unchanged) and hepatic/biliary elimination. Approximately 10-15% excreted in bile via feces.
Renal elimination (60-80% unchanged); biliary/fecal excretion accounts for 15-20%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic